EDGAR·FLOW

ALX ONCOLOGY HOLDINGS INC — Form 8-K

Filed November 16, 2026 · analyzed by the 8-K Agent
8-K ▲ Likely positive significance 28/100
What the filing says
ALX Oncology (market cap ~$18M) reported Q3 2026 net loss of $21.8M ($0.15/share) on essentially flat R&D spend of $17.5M vs. $17.4M YoY. Cash position strengthened to $147.2M (from $48.3M at year-end 2025), sufficient to fund operations through H1 2028. Key catalysts: ALX2004 Phase 1 safety/efficacy data expected December 2026 (35 patients enrolled); ASPEN-09-Breast Phase 2 topline from ~120 patients expected H2 2027. No counterparties, partnerships, or financing transactions disclosed.
Why this rating

Routine quarterly disclosure; cash raise extended runway substantially. Clinical timeline advancement is positive but no concrete data yet. Small relative to market cap.

View original filing on SEC.gov ↗ ALXO · stock on Yahoo Finance ↗

See more from November 16, 2026.

EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.